Taysha Gene Therapies, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Taysha Gene Therapies, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Taysha Gene Therapies, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 116 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 116 +720 Sep 30, 2024
Q2 2024 283 +1.42K Jun 30, 2024
Q1 2024 1.32K -230 -14.9% Mar 31, 2024
Q4 2023 -2.2K -2.68K -564% Dec 31, 2023
Q3 2023 -604 -838 -358% Sep 30, 2023
Q2 2023 -1.14K -1.28K -919% Jun 30, 2023
Q1 2023 1.55K +1.46K +1777% Mar 31, 2023
Q4 2022 475 +429 +940% Dec 31, 2022
Q3 2022 234 +211 +923% Sep 30, 2022
Q2 2022 139 +129 +1267% Jun 30, 2022
Q1 2022 82.4 Mar 31, 2022
Q4 2021 45.7 Dec 31, 2021
Q3 2021 22.9 Sep 30, 2021
Q2 2021 10.2 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.